CGT Industry Upgrading Series - Site Visit VI: Yichuang High-Tech Innovation Park Hosts Key Stakeholders to Advance Cell and Gene Therapy Ecosystem

Mar 01, 2024 09:21 CST Updated 09:21

Yeasen

Tool Enzyme Raw Materials and Diagnostic Product R&D, Manufacturer

VectorBuilder

Gene Delivery Technology Developer

Saifu Pharmaceutical

Preclinical CRO Service Provider

Legend Capital

Early-stage venture capital and growth-stage private equity investment institutions

Event Information

Conference Name:[No Need for Cutthroat Competition, Go Further] CGT Industry Upgrade Series · Park Tour – Stop 6: BeijingYichuang High-Tech Innovation Science Park

Organizer: Healthcare Innovative Ecosystem Alliance (HIEA)

Co-Organizers: Hangzhou Xingcheng Biotechnology, Yeasen, LePure Introduction, Austar Group (Hong Kong), VectorBuilder, Beijing T&L Biotechnology, Saifu Pharmaceutical,Legend Capital

Organizer: Arterial New Medicine

Supporting Organizations: Yichuang Gaoke Innovation Technology Park

Event Time:Thursday, March 7, 2024, 13:30

Event Venue:Lecture Hall, 1st Floor, Building 4, Yichuang Gaoke Innovation Technology Park, No. 2 Yard, Kechuang 6th Street, Beijing Economic-Technological Development Area

On-Site View of Yichuang Gaoke Innovation Technology Park:

场地5.png

Event Scale: 50 people/session

Event Partnership:

Ms. Fu 17851017836 (WeChat ID same as phone number)

Event Registration:

Capillaries 17782369627 (WeChat ID same)

Long-press to scan the QR code and register

小助手.jpg

Highlights

CGT from an Investment Perspective: Leveraging investor acumen to distill new pathways for capital operations by innovative pharmaceutical companies during discussions on investment and financing strategies in the CGT sector, thereby helping enterprises seize growth opportunities and navigate challenges.

Optimal Supply Chain Solution: Listen to Party A's needs, and supply chain enterprises jointly explore the most suitable solutions, striving to help innovative companies transition smoothly, rapidly, and cost-effectively from IND toBLA。

Strategic Insights for Large Enterprises: An in-depth analysis of how large enterprises can activate their internal innovation engines and build robust innovation ecosystems to ensure the continuous upgrading of their core competitiveness amidst increasingly fierce international competition and rapid technological change.

The “Yichuang Gaoke Innovation Technology Park Tour” marks the sixth stop in the park tour series. Similar events will be held in other industrial parks in the future to promote the continuous upgrading and development of the CGT industry. We look forward to engaging in discussions and fostering mutual progress with industry peers, thereby helping the CGT industry go further!

Event Agenda

■ 13：30-13：40

Host's Opening Remarks

Liu Xiao | Vice President of Business and Marketing, Hangzhou Xingcheng Biotechnology Co., Ltd.; Deputy Director of the MAH Special Committee, China Pharmaceutical Enterprise Management Association

■ 13：40-14：00

Keynote Speech 1 |How to Design and Build Compliant and Efficient ATMP Facilities

Kang Wei | Vice President of Strategic Consulting, Austar Group

■ 14：00-15：10

Panel 1 | How to Join Forces to Help CGT Companies Navigate from IND to BLA with Stability, Speed, and Cost Efficiency?

· Introduction to Core Competencies and Service Value

· How to Engage Constructively with Clients and Foster Collaborative Support

Wang Lijun | CEO, Xingcheng Biotechnology

Zhou Qihao | Vice President, Yeasen

Yu Xiaoyu | LePure BioService, R&D Director of CGT

Kang Wei | Vice President of Strategic Consulting, Austar Group

Xu Rong | VP of Technology, Beijing T&L Biotechnology Co.,Ltd.

Han Gang | Vice President, Saifu Pharmaceutical

Li Lianjie | VectorBuilder, Director of Business Development

■ 15：10-16：10

Panel 2 | Discussing Industrial Upgrading: Key CMC Points and Solutions for Gene and Cell Therapy

· Avoid generic discussions of regulations

· Discussion on Quality Control Strategies and Specific Service Cases

· Party A states its requirements, and Party B presents its solutions

Liu Yongjun | Chairman and Chief Scientist, Beilai Pharmaceutical

Zhang Huiyuan | Managing Partner, Quality Director, and Head of CMC at Chengnuo Medicine

Wang Lijun | CEO, Xingcheng Biotechnology

Zhou Qihao | Vice President, Yeasen

Yu Xiaoyu | R&D Director of CGT, LePure BioService

■ 16:10-16:30 Tea Break

■ 16：30-16：50

Keynote Speech 3 |Progress and Trends in the CGT Industry from an Investment Perspective

· Finance as a Tool: Understanding Capital Market Trends

· Industry as the Foundation: Current Status and Outlook of the CGT Sector

Dong Ao | Investment Manager, Legend Capital

■ 16：50-17：10

Dialogue with Large Enterprises |Large Enterprise Perspective: Making Innovation Sustainable

Li Xingfa | Senior Investment Director, China Resources Pharmaceutical

Song Gengshen | Deputy General Manager, Yuekang Pharmaceutical Group

Wu Chao | General Manager, VCBeat New Medicine (Moderator)

■ 17：10-18：10

Panel 3 | How Can CGT Companies Effectively “Raise and Spend Capital” in the New Landscape?

· Say goodbye to cookie-cutter roadshows with randomized conversations

· Insights and perspectives to help enterprises demonstrate their value

· Embrace “preparedness” and respect uncertainty

· Innovative One-to-Many Interview-Style Project Pitch

Zhang Jianmin | Distinguished Professor of “Peking Union Medical College Scholars”, Founder of Guodian Pharmaceutical

Mou Haidong | Head of IR, Yinzheng Gene

Pei Zheng｜Co-founder of Yisheng Biotechnology

Gu Wei Yue｜Chairman of Kite Medical

Geng Shaojun | Co-founder, T&L Biotechnology

Dong Ao｜Legend Capital Investment Manager(Host)

■ 18:30–20:30 Dinner Networking (By Invitation Only)

Guest Introduction

Liu Xiao

Hangzhou Xingcheng Biotechnology Co., Ltd. Vice President of Business and Marketing,

Vice Chairman of the MAH Special Committee, China Pharmaceutical Enterprise Management Association

Liu Xiao holds a Ph.D. in Strategy from the University of Montpellier, France; an EMBA from Nankai University; an M.Sc. in Biology from the University of Manchester; and pursued graduate studies in Finance at the University of Hong Kong. He is currently pursuing an M.Sc. in Psychology at Arizona State University, USA. He serves as an Industry Professor at UCMT and an Honorary Director of GDA. He is a Senior Engineer in Measurement, Testing, and Instrumentation across China.Dr. Liu acts as a thesis supervisor for DBA, MBA, and Healthcare Management doctoral candidates at the University of Montpellier, France. He is a Distinguished Lecturer for workshops at the Business School of the University of Hong Kong and Nankai University, a Lecturer for the Advanced Leadership Training Program in Biopharmaceuticals at Peking University Health Science Center, and a Guest Lecturer at Yihong Business School.He serves as Vice Chairman of the MAH Special Committee under the Chinese Pharmaceutical Enterprise Management Association, Chief Researcher at the Life Sciences Enterprise Research Center of E-Drug Manager, and Special Researcher at the China Biomedical Infrastructure Alliance. He is also the Planner and Host of the “ChatCGT” column.

Formerly served as Head of Marketing, Greater China, at Danaher Biotechnology Group, and held positions including Asia Pacific Marketing Director, Greater China Marketing Director, Consumables Sales Manager, Business Development Manager, and Product Manager at companies such as Cytiva, GE Life Sciences, PerkinElmer, and Thermo Fisher Scientific.

Wang Lijun

CEO of Hangzhou Xingcheng Biotechnology Co., Ltd.

Wang Lijun possesses over 20 years of comprehensive experience in the biopharmaceutical industry, with nearly 17 years dedicated to gene therapy, viral vector process development, and cGMP manufacturing. As an innovative leader in AAV production process development, he specializes in large-scale cell culture and viral vector purification, and is proficient in analytical methods. He has extensive GMP manufacturing experience with AAV, lentivirus, adenovirus, and oncolytic herpes simplex virus (oHSV). Well-versed in CMC regulations, he has participated in the design of multiple cGMP production facilities and has successfully led and delivered numerous clinical batches of viral vectors. He also brings rich team management experience. His previous employers include AGTC, Brammer Bio, and Encoded Therapeutics.

Zhou Qihao

Yeasen Vice President

Zhou Qihao joined Yeasen in 2013, advancing from a frontline sales representative to the company’s Vice President of Marketing. He possesses extensive practical experience in business operations and keen industry insights.

Yeasen specializes in the research, development, and manufacturing of upstream raw materials for the biotechnology industry, with applications in life science research, drug and vaccine development, and in vitro diagnostic testing. Guided by its mission to create value for customers and contribute to a healthier and happier world, Yeasen is committed to becoming a leader in the life science tools industry.

Kang Wei

Vice President of Strategic Consulting, Austar Group

Kang Wei has over 28 years of experience in the biopharmaceutical and pharmaceutical industries, having served as a Senior Expert, Subject Matter Expert (SME), and Management Representative at Novo Nordisk Engineering. As an expert in international biopharmaceutical engineering and consulting, he is responsible for front-end consulting, engineering design, project management, and quality validation for biopharmaceutical and pharmaceutical projects, bringing extensive project experience and profound industry insights. His consulting clients and projects include the Bill & Melinda Gates Foundation, Novo Nordisk, GSK, Novozymes, Boehringer Ingelheim, SANOFI, and WuXi Biologics. Currently serving as Vice President of Austar Group, he focuses on consulting, design, project management, and validation for pharmaceutical engineering projects. Collaborating with an international team of pharmaceutical experts, he provides specialized technical consulting to domestic and international clients in areas such as vaccines, monoclonal antibodies, Advanced Therapy Medicinal Products (ATMPs), and Antibody-Drug Conjugates (ADCs), ensuring compliance with standards from regulatory bodies including the FDA, EMA, WHO, and NMPA. Selected international organizations and speaking engagements:

1. 2015, Huntington IBC Life Sciences Biologics Development and Production (BDP), California, USA; Presentation Title: “Building China’s Biotechnology Manufacturing Capabilities”

2. 2016, ISPE BioProcess Development Symposium, Presentation Title - “Considerations for Biopharmaceutical Facilities from an Engineering Perspective”

3. 2017, ISPE BioPhorum, Presentation Title – “Best Practices for Biopharmaceutical Project Execution”

4. 2018, ISPE/CIPM Forum, Presentation Title - "Bridging Global Biologics to Local Projects"

5. 2019 ISPE Conference on “Innovative Technologies and Concepts for Biotechnology Facilities,” Presentation Title: “GMP Trends and Expectations for Cell Therapy Facilities”

6. 2020, ISPE/CIPM Forum, Presentation Title – “Case Sharing: Efficient and Compliant Biopharmaceutical Facilities”

Yu Xiaoyu

LePure BioService, Director of CGT R&D

Yu Xiaoyu has over 10 years of experience in the biopharmaceutical and life sciences industries. From 2012 to 2018, he worked at Hisun Pharmaceutical, where he was responsible for media development, R&D of new monoclonal antibody drugs, and cell line development. He is well-versed in key upstream biopharmaceutical technologies and possesses deep expertise and extensive experience in critical areas such as cell culture, cell line development, and media development. In 2018, he joined Kapsom Bio as a founding team member, leading the R&D of media and cell line products. Currently, he serves as the R&D Director of BioService CGT at LePure Biotechnology, where he spearheads the development of commercial HEK293 cell lines, culture media, and virus production-related products.

Xu Rong

Vice President of Technology, Beijing T&L Biotechnology Co., Ltd.

Xu Rong holds a Master’s degree in Biochemistry and Cell Biology from the Academy of Military Medical Sciences of the Chinese People's Liberation Army. With over 12 years of experience in the biopharmaceutical industry, she is well-versed in process development and clinical research for cell therapies, as well as the process development of biological macromolecules. She has completed the design and construction of GMP-compliant facilities and established quality systems and corresponding quality standards for GMP-grade products. During her tenure as Vice President of Technology at Beijing T&L Biotechnology Co., Ltd., she was primarily responsible for overseeing small-scale and pilot-scale production of GMP products, developing and revising standard operating procedures (SOPs), and implementing the quality management system.

Throughout my 12-year career, I have focused on process development, quality analysis, clinical research, and the establishment of quality standards for cell-based therapies. My scope later expanded to include upstream product development for cell therapies, where I established a recombinant protein expression platform and defined product quality standards. To meet the demand for GMP-grade materials among cell therapy companies, I led the Quality Department in conducting product quality research, establishing quality standards, and performing quality assessments. As our product pipeline diversified and expanded, I implemented a full product lifecycle management concept and achieved comprehensive, unified planning across the entire product development process.

Han Gang

Saifu Pharmaceutical, Vice President

Ph.D., Associate Research Fellow, Academy of Military Medical Sciences. Former Senior Project Leader at the National Beijing Center for Drug Safety Evaluation and Research, Institute of Toxicology and Pharmacology, Academy of Military Medical Sciences. Young Member of the Professional Committee on Toxicology of Traditional Chinese Medicine and Natural Drugs, Chinese Society of Toxicology; Young Member of the Sub-committee on Safety Evaluation of Traditional Chinese Medicine, China Association of Chinese Medicine; Standing Committee Member of the Youth Committee on Environment and Health, Beijing Society of Environmental Mutagens; Council Member, Hebei Province Laboratory Animal Science Association. With nearly two decades of experience in drug safety evaluation, he has undertaken more than 100 safety assessment studies and possesses extensive expertise in the pharmacological efficacy, pharmacokinetics, and safety evaluation of stem cells, antibody drugs, chemical drugs, and traditional Chinese medicines. He spearheaded his institution’s GLP certification process, successfully obtaining nine GLP qualifications from the National Medical Products Administration in a single review. He served as the principal investigator for sub-projects under more than ten major national special projects and National Natural Science Foundation grants. He has published over 20 papers in domestic and international journals, been granted five invention patents and more than ten utility model patents, received the Second Prize for Military Scientific and Technological Progress, and was awarded a Third-Class Merit by the military.

Jet Li

VectorBuilder, Director of Business Development

Li Lianjie has nearly a decade of experience in the biotechnology industry. He joined VectorBuilder in 2020, successively serving as Vice President of Sales for the Research Services Division and Director of the Business Development Department, accumulating extensive practical experience in business operations and expansion.

Liu Yongjun

Beilai Pharmaceutical, Chairman and Chief Scientist

Dr. Liu Yongjun, Ph.D., is the Chairman and Chief Scientist of Beijing Beilai Pharmaceutical Co., Ltd. He served as a Visiting Scholar at the Stem Cell Research Center of the University of California, Irvine (UCI). He is recognized as a “Yiqilin” Leading Talent in Beijing, serves as the Chairman of the CGT Drug Quality Research Professional Committee under the China Association for Pharmaceutical Quality, holds the position of Vice President of the Chinese Committee for Physical and Mental Health of Adolescents, and is an Executive Director of the Chinese Society for Biopharmaceuticals.

Dedicated to basic scientific research and clinical translation of stem cells, achieving significant research outcomes in the fields of stem cell tissue engineering, stem cell-based drug development, and genetically engineered drug development. Participated in the drafting of multiple guidelines for the preparation of stem cell preparations and quality management of cell banks. Obtained four Investigational New Drug (IND) approvals from the National Medical Products Administration (NMPA) and two IND approvals from the U.S. Food and Drug Administration (FDA).

Zhang Huiyuan

Chengnuo Medicine, Managing Partner

Quality Director and Head of CMC

Zhang Huiyuan, Ph.D. in Physiology from Peking University and Visiting Scholar at the Wellcome-MRC Cambridge Stem Cell Institute. He serves as Executive Partner, Quality Director, and Head of CMC at Beijing Chengnuo Medical Technology Co., Ltd., where he led the development of China’s first induced pluripotent stem cell (iPSC)-derived cellular therapy product to receive Investigational New Drug (IND) approval. With over nine years of research and professional experience in the iPSC field, he possesses comprehensive expertise spanning early-stage development, process translation for manufacturing, and regulatory submission for clinical trials (IND) of novel iPSC-derived cellular therapies. His work has focused on developing manufacturing processes for off-the-shelf allogeneic iPSC-derived cellular products, as well as establishing quality assessment methods and quality standards tailored to these novel therapeutics. Dr. Zhang is recognized as a Beijing Science and Technology Star and an Yiqilin Talent in the Beijing Economic-Technological Development Area.

Li Xingfa

CR Pharma, Senior Investment Director

Li Xingfa holds a master’s degree from China Pharmaceutical University and brings over 20 years of experience in the pharmaceutical industry. His career has spanned R&D, clinical operations and regulatory affairs, market access and commercialization, as well as strategy, business development, and investment, with work experience in both domestic and international markets. He joined China Resources Pharmaceutical Group in 2012, focusing on external innovation and partnerships as well as innovative pharmaceutical investments. He has led and participated in multiple in-licensing projects, large-scale M&A transactions, and industrial fund investments. He currently serves as Senior Investment Director at China Resources Pharmaceutical Group.

Song Gengshen

Yuekang Pharmaceutical Group, Vice General Manager

Song Gengshen, Ph.D., Senior Engineer (Professor Level), Dean of the Institute of Pharmaceutical Research at Yuekang Pharmaceutical Group Co., Ltd., and Director of the National-Local Joint Engineering Center for Nucleic Acid Drugs. He concurrently serves as Vice Chairman and Secretary-General of the Biomarker Professional Committee of the Chinese Research Hospital Association, Vice Chairman of the Pharmaceutical Excipients Professional Committee of the Chinese Pharmaceutical Association, Member of the Drug R&D Professional Committee of the China Association for Pharmaceutical Innovation, and Member of the Nucleic Acid Vaccine Branch of the China Vaccines Industry Association. His work focuses on the research and development of mRNA therapies, small nucleic acid drugs, and LNP delivery systems. He has led multiple R&D pipelines for mRNA vaccines, small nucleic acid drugs, and peptide drugs.

Zhang Jianmin

“Peking Union Medical College Scholar” Distinguished Professor, Founder of Guodian Medicine

Professor Zhang Jianmin, Distinguished “Peking Union Medical College Scholar,” and Founder of Guodian Pharmaceutical. He is a Professor and Doctoral Supervisor at the Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), and Director of the CAMS Key Laboratory of T Cells and Immunotherapy. Previously, he served as a Postdoctoral Fellow in the Department of Immunobiology at Yale University, and as a Lecturer and Professor in the Department of Neurobiology at Johns Hopkins University. His primary research focuses on the pathogenesis and therapeutic targets of neurodegenerative diseases and cancer. He has published more than 80 papers in international scientific journals, including cover features in Cell, as well as articles in Nature Immunology, Cell Discovery, and Signal Transduction and Targeted Therapy (STTT). He concurrently serves as a Member of the Central Committee of the Chinese Peasants and Workers Democratic Party (CPWDP), Deputy Director of the CPWDP Central Committee’s Working Committee for Healthy China Development, Director of the Medicine and Biotechnology Branch, Standing Committee Member of the Professional Committee on Tumor Biotherapy under the China Anti-Cancer Association, Committee Member of the Synthetic Biotechnology Branch of the China Association of Pharmaceutical Biotechnology, Editorial Board Member and Reviewer for multiple international journals, and Review Expert for the National Natural Science Foundation of China and the Ministry of Science and Technology.

Mou Haidong

Head of IR, Yingzheng Gene

Mou Haidong holds a Master’s degree in Pharmacognosy and a Bachelor’s degree in Pharmacy from Peking University Health Science Center, along with a second bachelor’s degree in Economics from Peking University. He has extensive experience in instrumental analysis (including mass spectrometry and chromatography) and methodology development, and has participated in the regulatory registration and filing of products such as obinutuzumab and cobimetinib in China. With over six years of experience in early-stage primary market investments in the healthcare sector, he has been involved in investments in companies including Ascentage Pharma, Viatris, Shengxin Biology, Yinzheng Gene, and Xingchen Jiyin. Additionally, he has played a deep role in fund incubation and project-specific initiatives for Yinzheng Gene, covering project initiation and investor relations.

Geng Shaojun

Co-founder, Beijing T&L Biotechnology Co.,Ltd.

Geng Shaojun holds an MBA from the University of Management and Technology (UMT) in the United States. He is a member of the Biomedical Innovation Association and the Medical-Engineering Interdisciplinary Association, with over 20 years of team management experience. For the past decade, he has been engaged in the cell therapy and gene therapy industries, possessing in-depth knowledge of the upstream sector. He is dedicated to fostering the steady growth of startups, with a particular focus on corporate strategic planning and culture building, industry landscape research, and business model design. He has facilitated collaborative partnerships with multiple universities and participated in the filing of two invention patents. He brings extensive practical experience in building teams from the ground up, optimizing organizational structures, initiating key product projects, and comprehensive operational management.

*The above guests are listed in agenda order, not by rank.

Company Profile

Hangzhou Xingcheng Biotechnology Co., Ltd.

CoJourney is a professional gene and cell therapy CDMO integrating plasmid, viral vector, and mRNA production, preparation, and analytical testing. The company has successful experience in filing Investigational New Drug (IND) applications for plasmids and viral vectors in both China and the United States, achieving zero deficiency letters. CoJourney provides customized services including process development, cGMP manufacturing, analytical method development, and product release testing for plasmids, viral vectors, and mRNA.Founded by senior CMC experts with commercialization experience in the gene and cell therapy field, along with accomplished scientists and entrepreneurs, CoJourney operates dual headquarters in Zhejiang, China, and Pennsylvania, USA. The company has established GMP manufacturing facilities for plasmids, viral vectors, and mRNA that comply with FDA, EU, and NMPA regulations. Equipped with advanced production and testing instruments, our team possesses extensive expertise in process development and practical execution. Upholding the philosophy of "Action Rooted in Sincerity," we leverage robust processes that exceed industry standards to ensure high-purity, high-yield, and cost-effective quality services for our partners, supporting plasmid, viral vector, and mRNA preparation at various production scales from R&D to GMP levels.

Yeasen

Yeasen Biotechnology (Shanghai) Co., Ltd. is a high-tech enterprise focused on core raw materials in the upstream life science industry chain, engaged in the research and development, production, and sales of biological reagents across three major categories: molecular, protein, and cellular. By integrating technological development pathways for molecular enzymes, proteins, antibodies, nucleic acids, and cells, Yeasen has become one of the few companies in China that simultaneously covers all three major categories of biological reagents, possessing both independent R&D capabilities for core technologies and large-scale production capacity. The company develops, produces, and sells thousands of types of biological reagents, meeting customers’ integrated procurement needs for various types of biological reagents. Its core product portfolio covers the qPCR series,NGSReverse Transcription Series, Nucleic Acid Extraction and Purification Series, PCR Series, Molecular Cloning Series, In Vitro Transcription Series, Antibodies, Protein Purification Series, Protein Analysis Series, Recombinant Proteins, Cell Analysis Series, Cell Culture Series, Cell Transfection Series, Reporter Gene Assay Series, and other categories, widely used in life science research, diagnostic testing, biopharmaceuticals, and other fields.

LePure Biotech

Shanghai LePure Biotechnology Co., Ltd. was established in 2011 and has incorporated outstanding brands such as Geshi Fluid, Kangsheng Biology, and Stanleys through an external growth strategy. Its current business scope covers multiple application scenarios, including cell culture, filtration and purification, single-use systems, and industrial-grade contamination-controlled clean solutions. It has now become a widely recognized leading supplier providing end-to-end upstream biopharmaceutical processing solutions.

Mission and Vision: Driven by technological innovation, we provide high-quality bioprocessing solutions and are committed to becoming the most trusted partner for global biopharmaceutical companies.

Austar Group

Hong Kong Austar Group is an advanced technology-driven provider of pharmaceutical engineering solutions, possessing comprehensive knowledge and expertise in life sciences process technology, applications, industry regulatory guidelines, and best practices. The company helps clients address challenges related to quality, compliance, and operational excellence, and is committed to delivering turnkey solutions encompassing equipment, engineering, services, and consumables, thereby driving industry progress and creating sustained value.

Austar Life Science Equipment and Consumables is a core business unit of Austar Group. By introducing advanced research, industrial consumables, and instrumentation from Europe and the United States, we provide comprehensive, high-quality solutions encompassing consumables, equipment, and services to clients in the pharmaceutical, life sciences, laboratory animal science, biosafety, medical devices, health supplements, and daily chemical industries. We specifically support customers requiring compliance with EU GMP, cGMP, COS, and other relevant certifications, while offering diversified technical guidance, training, and application support.

VectorBuilder

VectorBuilder (Guangzhou) Co., Ltd., founded in 2014 by the world-renowned molecular biologist Dr. Lan Tian, is a leading enterprise in gene delivery. The company provides comprehensive services across the entire gene delivery industry chain, including research vector construction, gene delivery CRO, and gene vector CDMO. Currently, VectorBuilder has established more than 10 subsidiaries and offices worldwide and was recognized as a global unicorn in 2023. VectorBuilder pioneered the "VectorBuilder" platform, ushering in an era of commercialized custom gene vectors. It has served over 4,000 research institutions and pharmaceutical companies in more than 90 countries and regions, with its contributions widely cited in thousands of articles published in top-tier scientific journals such as Science, Nature, and Cell. Since entering the clinical market, its gene therapy CRO and CDMO projects have covered multiple countries and regions, including North America, Europe, and Japan.

VectorBuilder provides end-to-end services from research to clinical applications:

(1) Research Vectors and Viral Services: Vector construction, viral packaging, etc.

(2) CRO Services: AAV capsid directed evolution, library construction, mRNA gene delivery solutions, stable cell line generation, etc.

(3) CDMO Services: Process development, analytical method development, plasmid preparation, virus preparation, IVT mRNA and LNP preparation, cell bank establishment, etc.

VectorBuilder is committed to systematically overcoming key technical bottlenecks in the gene delivery industry, empowering basic scientific research, accelerating the clinical application of gene therapies, improving human health, and creating irreplaceable value for the world.

Beijing T&L Biotechnology

Beijing T&L Biotechnology Co.,Ltd. specializes in the research, development, and production of GMP-grade raw materials and reagents for cell and gene therapy (CGT), providing comprehensive product and service solutions to CGT users. Its product portfolio includes magnetic beads for cell sorting, eukaryotic/prokaryotic recombinant proteins, serum-free culture media, and cell culture kits.

The company has been honored with titles such as “National High-Tech Enterprise” and “Beijing Specialized, Refined, Differential, and Innovative SME.” It operates a 3,200 m² R&D laboratory and GMP-grade cleanroom facilities, including platforms for magnetic bead-based cell separation development, eukaryotic and prokaryotic protein expression engineering, and serum-free culture medium development. The company is certified under both ISO 13485 and ISO 9001 quality management systems, and certain products have obtained U.S. FDA Drug Master File (DMF) registration.

Saifu Pharmaceutical

Saifu Pharmaceutical is committed to becoming a world-class, one-stop pharmaceutical CRO service provider. It delivers top-tier pharmaceutical CRO evaluation services and integrates technical development, financing, and innovative drug product commercialization support to offer comprehensive R&D planning for enterprises. By accelerating the development of innovative drugs, Saifu Pharmaceutical helps companies achieve faster growth. The company comprises departments specializing in pharmaceutical R&D consulting, NMPA/FDA regulatory submissions, antibody drug discovery, drug screening, druggability assessment, pharmacology and efficacy studies, drug metabolism analysis, non-clinical safety evaluation, and bioanalysis, providing one-stop professional services for pharmaceutical R&D enterprises.

The company has successively been honored with titles such as National Specialized, Refined, Differential, and Innovative “Little Giant” Enterprise, National High-Tech Enterprise, Beijing Municipal Enterprise Science and Technology Research and Development Institution, and Zhongguancun High-Tech Enterprise, and operates two postdoctoral research workstations. Saifu Pharmaceutical possesses the Jingnan Gu’an Drug GLP Center, Pharmacology and Efficacy Center, Pharmacokinetic Analysis Center, Shenzhen Center (Saifu Jiayuan) Ophthalmic Drug Evaluation Center, Drug Innovation Research Center, Drug Screening Center, Antibody Discovery Center, Central Laboratory, and its U.S. office responsible for FDA registration filings.

Legend Capital

Legend Capital, established in April 2001, is a leading fund management company in China specializing in early-stage venture capital and growth-stage private equity investments. Over the past two decades, Legend Capital has adhered to international standards and created best practices in fund operations and management. Through its proactive value-added service system, Legend Capital fosters corporate innovation and growth, consistently delivering strong investment returns across multiple sectors while promoting industrial advancement and social development in China. With the vision of “becoming an investment firm with global influence,” Legend Capital upholds the core value of “Wealth with Integrity” and actively fulfills its social responsibilities.

Legend Capital has maintained a deep focus on investments in the healthcare sector, systematically building its portfolio across the broader health industry. Notable portfolio companies in this field include Pharmaron (300759.SZ) (03759.HK), WuXi AppTec (603259.SH) (02359.HK), and WuXi Biologics (02269.HK),Innovent Biologics(01801.HK), New Horizon Health (06606.HK), and Mingde Biology (002932.SZ), among other leading companies in their respective niche sectors, are listed on the A-share and Hong Kong stock markets.

Yichuang High-Tech Innovation Park

Yichuang Gaoke Innovation Technology Park is located at No. 2 Courtyard, Kechuang 6th Street, Beijing Economic-Technological Development Area (BDA). It falls within the scope of both the “One Zone, Sixteen Parks” initiative of Zhongguancun Science Park and the BDA Free Trade Zone, allowing enterprises to benefit from dual policy support. Focusing on biopharmaceuticals and general health—one of the four pillar industries of the BDA—the park features eight high-rise buildings and six podium structures for enterprises, with a total gross floor area of nearly 100,000 square meters. The occupancy rate stands at 90%, while the concentration of biopharmaceutical companies approaches 100%. After three years of operation, the park is home to nearly 100 enterprises, including eight specialized, refined, distinctive, and innovative (“SRDI”) enterprises, more than 20 national high-tech enterprises, over ten award-winning startups from entrepreneurship competitions, and more than ten talents recognized at municipal and district levels. The park provides professional contract research organization (CRO) services, shared laboratory platforms, instrument and equipment platforms, Class 10,000 cleanroom spaces, and other specialized facilities and industrial services tailored for biopharmaceutical companies. Additionally, it offers financial support through direct and co-investment via its own funds to help enterprises grow and expand. The park has been honored as a High-Quality Park certified by the Beijing Municipal Science & Technology Commission, a Mass Entrepreneurship and Innovation Base accredited by the Beijing Municipal Bureau of Economy and Information Technology, a Model Business Incubation Base recognized by the Beijing Municipal Human Resources and Social Security Bureau, and an Academician and Expert Innovation Service Center Base designated by the Beijing Association for Science and Technology. The park will continue to contribute to industrial innovation and sector development.

VBPharma

VCBeat New Medicine isVCBeatAs a media and research platform under the VCBeat umbrella focused on biomedicine, it delivers “in-depth” and “incremental” communication value to innovators and entrepreneurs through both content and operations. On the content front, key offerings include exclusive financing announcements, corporate interviews, the “Drug Developers” column, in-depth industry analyses, and sector reports. Operationally, through its branded program “VB Think Tank,” it focuses on practical challenges, discusses industrial trends, and fosters tangible collaborations through the exchange of ideas.

*The above organizations are listed in agenda order, not in any particular order.

Event Scale: 50 people/session

Event Collaboration:

Ms. Fu 17851017836 (WeChat ID same)

Event Registration:

Capillaries 17782369627 (WeChat ID same as phone number)